Literature DB >> 22049034

Epidemiology of leishmaniasis in Spain based on hospitalization records (1997-2008).

Ruth Gil-Prieto1, Stefan Walter, Jorge Alvar, Angel Gil de Miguel.   

Abstract

All the records from the Spanish information system for hospital data of patients diagnosed with leishmaniasis during a 12-year period (1997-2008) were studied. The 2,028 individuals were hospitalized because of leishmaniasis, as indicated by the principal diagnostic code. The average hospitalization rate was 0.41/100,000 inhabitants. One-third of them were co-infected with human immunodeficiency virus (HIV). The incidence of hospitalization in the adult population with leishmaniasis co-infected with HIV increased with age, peaked at 35-39 years of age and subsequently declined. In the pediatric population, all leishmaniasis cases occurred in HIV-negative children. Incidence of hospitalizations was highest in Madrid and in the Mediterranean coast. The cost per inpatient hospital care was $9,601 corresponding to an annual direct cost of more than $1.5 million for inpatient care alone. The economical burden of leishmaniasis is not neglectable and in the 12-year study period it represented more than $19 million.

Entities:  

Mesh:

Year:  2011        PMID: 22049034      PMCID: PMC3205626          DOI: 10.4269/ajtmh.2011.11-0310

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  18 in total

1.  [The quality assessment from the minimum basic hospital discharge data set].

Authors:  S Peiró; J Librero
Journal:  Rev Neurol       Date:  1999 Oct 1-15       Impact factor: 0.870

2.  Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients.

Authors:  Cecilia Tortajada; Bernardo Pérez-Cuevas; Asuncion Moreno; Esteban Martínez; Jose Mallolas; Felipe García; Eugenia Valls; José M Miró; Esther De Lazzari; José M Gatell
Journal:  J Acquir Immune Defic Syndr       Date:  2002-07-01       Impact factor: 3.731

3.  [Evaluation of the socioeconomic costs of cutaneous leishmaniasis in French Guiana].

Authors:  J P Dedet; B Pillot; M Gentilini
Journal:  Rev Epidemiol Sante Publique       Date:  1991       Impact factor: 1.019

Review 4.  Leishmania and human immunodeficiency virus coinfection: the first 10 years.

Authors:  J Alvar; C Cañavate; B Gutiérrez-Solar; M Jiménez; F Laguna; R López-Vélez; R Molina; J Moreno
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

5.  Leishmania in discarded syringes from intravenous drug users.

Authors:  I Cruz; M A Morales; I Noguer; A Rodríguez; J Alvar
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

6.  Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts.

Authors:  J Kubar; P Marty; A Lelièvre; J F Quaranta; P Staccini; C Caroli-Bosc; Y Le Fichoux
Journal:  AIDS       Date:  1998-11-12       Impact factor: 4.177

Review 7.  Leishmania/HIV co-infections: epidemiology in Europe.

Authors:  P Desjeux; J Alvar
Journal:  Ann Trop Med Parasitol       Date:  2003-10

8.  Leishmaniasis eco-epidemiology in the Alpujarra region (Granada Province, southern Spain).

Authors:  C Acedo Sánchez; J Martín Sánchez; I D Vélez Bernal; M C Sanchís Marín; M Louassini; J A Maldonado; F Morillas Márquez
Journal:  Int J Parasitol       Date:  1996-03       Impact factor: 3.981

9.  Leishmanin reaction in the human population of a highly endemic focus of canine leishmaniasis in Alpes-Maritimes, France.

Authors:  P Marty; Y Le Fichoux; D Giordana; A Brugnetti
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 May-Jun       Impact factor: 2.184

10.  Frequency of visceral leishmaniasis relapses in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.

Authors:  Jose A Mira; Juan E Corzo; Antonio Rivero; Juan Macias; Fernando Lozano De Leon; Julian Torre-Cisneros; Jesus Gomez-Mateos; Rafael Jurado; Juan A Pineda
Journal:  Am J Trop Med Hyg       Date:  2004-03       Impact factor: 2.345

View more
  15 in total

1.  [Community outbreak of leishmaniasis in the southern area of the community of Madrid].

Authors:  Mar Noguerol Álvarez; Juan Víctor San Martín López; Marta Aguado Lobo; Pilar Aparicio Azcárraga
Journal:  Aten Primaria       Date:  2012-06-20       Impact factor: 1.137

2.  Development of visceral leishmaniasis in an HIV(+) patient upon immune reconstitution following the initiation of antiretroviral therapy.

Authors:  Benjamin T Schleenvoigt; Ralf Ignatius; Michael Baier; Thomas Schneider; Marko Weber; Stefan Hagel; Christina Forstner; Mathias W Pletz
Journal:  Infection       Date:  2015-06-30       Impact factor: 3.553

3.  Visceral Leishmaniasis in Hospitalized HIV-Infected Patients in Pernambuco, Brazil.

Authors:  Diego Lins Guedes; Zulma Medeiros; Elis Dionísio da Silva; Audrey Violeta Martins de Vasconcelos; Mariana Santana da Silva; Maria Almerice Lopes da Silva; Paulo Sérgio Ramos de Araújo; Demócrito de Barros Miranda-Filho
Journal:  Am J Trop Med Hyg       Date:  2018-12       Impact factor: 2.345

4.  Medical Problems of Way of St. James Pilgrimage.

Authors:  Peter Felkai
Journal:  J Relig Health       Date:  2019-04

5.  Is Visceral Leishmaniasis Different in Immunocompromised Patients Without Human Immunodeficiency Virus? A Comparative, Multicenter Retrospective Cohort Analysis.

Authors:  José M Ramos; Rafael León; Esperanza Merino; Marta Montero; Asunción Aljibe; Marino Blanes; Sergio Reus; Vicente Boix; Miguel Salavert; Joaquín Portilla
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

6.  Hospitalization for Chagas disease, dengue, filariasis, leishmaniasis, schistosomiasis, strongyloidiasis, and Taenia solium taeniasis/cysticercosis, Italy, 2011-2016.

Authors:  Marta Tilli; Annarita Botta; Alessandro Bartoloni; Giampaolo Corti; Lorenzo Zammarchi
Journal:  Infection       Date:  2020-05-16       Impact factor: 3.553

7.  Co-infection of visceral leishmaniasis and HIV-1: a surviving case in China and review of treatment strategies.

Authors:  Shihui Song; Xi'en Gui; Liren Guan
Journal:  Emerg Microbes Infect       Date:  2014-04-09       Impact factor: 7.163

Review 8.  Visceral leishmaniasis and HIV coinfection in the Mediterranean region.

Authors:  Begoña Monge-Maillo; Francesca F Norman; Israel Cruz; Jorge Alvar; Rogelio López-Vélez
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

9.  Epidemiological changes in leishmaniasis in Spain according to hospitalization-based records, 1997-2011: raising awareness towards leishmaniasis in non-HIV patients.

Authors:  Zaida Herrador; Alin Gherasim; B Carolina Jimenez; Maria del sol Granados; Marisol Granados; Juan Victor San Martín; Pilar Aparicio
Journal:  PLoS Negl Trop Dis       Date:  2015-03-10

Review 10.  Decentralized control of human visceral leishmaniasis in endemic urban areas of Brazil: a literature review.

Authors:  Sonia S Menon; Rodolfo Rossi; Leon Nshimyumukiza; Kate Zinszer
Journal:  Trop Med Health       Date:  2016-04-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.